Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Emergent BioSolutions has completed a repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028, reducing the outstanding debt balance to approximately $364.7 million. The company executed this repurchase at an average price of 90.6% of face value, deploying about $68 million of cash, demonstrating disciplin…
Ambev (ABEV) combines steady cash generation, an attractive 5.6% yield, and recent margin improvement with a buyback program — qualities that can attract flows as Brazil’s election period increases risk aversion. Trade idea: buy ABEV at $3.03, target $3.45, stop $2.70, mid-term (45 trading days).
A group of app developers has filed a £2 billion ($2.7 billion) legal claim in London accusing Apple Inc of applying stricter app tracking rules to outside developers than to its own services. The suit, lodged at the Competition Appeal Tribunal, centers on Apple’s App Tracking Transparency feature introduced in 2021 and asserts the policy harmed bu…
Metlen Energy & Metals saw its shares climb 2.5% following the signing of a ten-year Power Purchase Agreement with Coca-Cola Tria Epsilon. The contract covers the full electricity output of a roughly 12 MW photovoltaic facility in Mikro Perivolaki, Velestino, expected to generate about 16.5 GWh annually. The arrangement aligns with Coca-Cola HBC's …
Broadcom delivered another blowout AI quarter (Q3 revenue $29.59B; AI chips $16.7B, +221% YoY) and guided to $34.8B for Q4. The business is re-rating toward an infrastructure-software + custom AI accelerator profile that supports higher multiples — but those multiples are already steep. This trade idea buys a controlled long with a clear stop, bett…
Vertiv's core power and thermal portfolio, a $15B backlog and a strategic acquisition announced 09/03/2026 create a high-conviction trade setup. Technicals show the stock has cooled off from lofty levels and fundamentals—free cash flow of $2.93B and 24% sales growth last quarter—support a mid-to-long-term rebound. Entry $258.00, stop $225.00, targe…
Saia, Inc. releases its less-than-truckload (LTL) shipment and tonnage data for July and August 2026, showing increases in shipments per workday, tonnage per workday, and weight per shipment compared to the same months in 2025. These gains indicate solid operational performance in the third quarter so far, though the company cautions actual results…
Dyne Therapeutics announced preclinical data supporting the development of four novel investigational therapies targeting Duchenne Muscular Dystrophy (DMD) mutations amenable to exon skipping of 44, 45, 53, and 55. These candidates, based on the same FORCE™ platform as their lead drug under FDA review, demonstrated promising in vitro and in vivo re…
Trevi Therapeutics announced that senior executives will participate in several major healthcare and IPF-related conferences in September 2026, presenting updates on their investigational therapy Haduvio™ (oral nalbuphine ER) intended to treat chronic cough associated with IPF, non-IPF ILD, and refractory chronic cough. The company highlighted the …
Eikon Therapeutics announced the appointment of Dr. Ching-Pin Chang as Executive Vice President and Chief Scientific Officer. Dr. Chang brings over 20 years of experience in academic medicine and biopharmaceutical drug discovery, having held key roles at Bristol Myers Squibb, Gilead Sciences, and MyoKardia. His extensive expertise in translational …
Electra Battery Materials Corporation is progressing with the construction of Canada’s only cobalt sulfate refinery in Ontario as part of its strategic plan to strengthen North America's critical minerals supply chain. The company is actively engaging with investors, industry participants, and government bodies through multiple September conference…
Rekor Systems, Inc. has terminated its two remaining long-term real estate leases in the US and Israel, resulting in elimination of ongoing rent obligations and generating over $2 million in annual cost savings. The company used $2.8 million in cash to reduce $10 million in lease liabilities, improving operating leverage and aligning cost structure…
TG Therapeutics announced that CEO Michael S. Weiss will participate in a fireside chat at the Cantor Global Healthcare Conference on September 9, 2026. The company is a commercial-stage biotech focused on treatments for B-cell diseases, with its FDA-approved drug BRIUMVI for relapsing multiple sclerosis.
Structure Therapeutics, a clinical-stage biopharmaceutical company focused on oral small molecule therapeutics for metabolic diseases, will participate in three leading healthcare investment conferences in September 2026, including Cantor Global Healthcare, Morgan Stanley Global Healthcare, and Bernstein’s Healthcare Forum. Management will hold fir…
Crescent Biopharma, a clinical-stage biotech company focusing on innovative cancer therapies, announced its management will present at the 2026 Cantor Global Healthcare Conference and Morgan Stanley Global Healthcare Conference in September. The presentations will highlight the company's pipeline developments including a PD-1 x VEGF bispecific anti…
The FDA has granted Fast Track designation to Liquidia Corporation's inhaled powder drug YUTREPIA (treprostinil) for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-RP), a condition with significant unmet medical need and no approved therapies in the United States. This designation will help expedite the development an…
Helus Pharma announced that CEO Michael Halstead will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York. The company is advancing its clinical-stage programs for proprietary serotonergic agonists aimed at treating depression and anxiety, including a Phase 3 candidate with FDA Breakthrough Therapy Designation…
Hillman Solutions Corp., a leading hardware product provider, has completed its acquisition of Kanebridge, LLC, a master distributor of industrial fasteners, for approximately $315 million. This strategic move significantly expands Hillman's industrial addressable market to around $3 billion and establishes its first U.S. master distribution platfo…
American Express remains a premium payment network and card issuer: high ROE, strong free cash flow, and a durable merchant network support a buy. Valuation is rich but not irrational relative to fundamentals. This trade idea proposes a mid-term position with a conservative stop and a realistic target that captures a re-rating back toward the 52-we…
Obsidian Energy (OBE) is showing constructive technicals, has solid liquidity after recent asset moves, and is trading below $1B market cap. With the stock at $12.20, multiple catalysts and a tight trade plan offer a favorable risk/reward for a mid-term swing trade over the next 45 trading days.
Micron is sitting on the economic winners of the AI build-out: HBM and data-center DRAM. Balance-sheet strength, $26.2B in free cash flow, and near-term sell-side estimates that imply $50.8B of revenue for the quarter support a bullish trade into Q4 2026. This trade idea outlines an entry, stop, and target with a 45-trading-day horizon designed to …
Amwell received Frost & Sullivan's 2026 Technology Innovation Leadership Recognition for its unified technology platform that addresses healthcare fragmentation by integrating consumer experiences, clinician workflows, care programs, and partner solutions. The award highlights Amwell’s innovation and business impact in creating a connected infrastr…
Alterity Therapeutics, a biotechnology company focused on neurodegenerative diseases, announced that CEO David Stamler will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026. The company is preparing for a Phase 3 pivotal trial for its lead drug ATH434, which has shown promising results in Phase 2 trials for Multiple Sy…
Polestar said on Sept. 3 that it has lowered its full-year delivery forecast after U.S. authorities barred the China-linked automaker from selling vehicles in the United States from model year 2027 onwards. The decision comes as the company reported weaker revenue, narrowed losses versus a year earlier, significant restructuring charges tied to its…
Azimut Holding SpA rose 3.6% to €39.26 after Deutsche Bank upgraded the stock to 'buy' and lifted its 12-month price target to €46 from €35. The upgrade cited strong first-half 2026 results, including double-digit recurring revenue and recurring net profit growth and record assets under management, along with a new share buyback and a capital retur…
